Purpose We hypothesized that whole-body metabolic tumor volume (MTVwb) could be used to supplement non-small cell lung cancer (NSCLC) staging due to its independent prognostic value. The goal of this study was to develop and validate a novel MTVwb risk stratification system to supplement NSCLC staging. Methods We performed an IRB-approved retrospective review of 935 patients with NSCLC and FDG-avid tumor divided into modeling and validation cohorts based on the type of PET/CT scanner used for imaging. In addition, sensitivity analysis was conducted by dividing the patient population into two randomized cohorts. Cox regression and Kaplan-Meier survival analyses were performed to determine the prognostic value of the MTVwb risk stratification system. Results The cut-off values (10.0, 53.4 and 155.0 mL) between the MTVwb quartiles of the modeling cohort were applied to both the modeling and validation cohorts to determine each patient's MTVwb risk stratum. The survival analyses showed that a lower MTVwb risk stratum was associated with better overall survival (all p < 0.01), independent of TNM stage together with other clinical prognostic factors, and the discriminatory power of the MTVwb risk stratification system, as measured by Gönen and Heller's concordance index, was not significantly different from that of TNM stage in both cohorts. Also, the prognostic value of the MTVwb risk stratum was robust in the two randomized cohorts. The discordance rate between the MTVwb risk stratum and TNM stage or substage was 45.1% in the modeling cohort and 50.3% in the validation cohort. Conclusion This study developed and validated a novel MTVwb risk stratification system, which has prognostic value independent of the TNM stage and other clinical prognostic factors in NSCLC, suggesting that it could be used for further NSCLC pretreatment assessment and for refining treatment decisions in individual patients.
Introduction
Current standard-of-care treatment and prognostic assessment of non-small cell lung cancer (NSCLC) depend primarily on TNM staging [1] . The TNM staging system lacks quantitative volumetric assessment of overall tumor burden [1] , and there are substantial variations in patient survival even within the same TNM stage following standard treatment [1] , suggesting that further pretreatment assessment of NSCLC to reduce the heterogeneity of tumor burden within the TNM stage group may allow better treatment selection and may improve clinical outcome. Whole-body metabolic tumor volume (MTVwb) measured on baseline FDG PET/CT has been shown to be of prognostic value independent of TNM stage, tumor standardized uptake value (SUV), and other clinical prognostic indicators [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, it cannot be easily used clinically as an interval measurement. Although MTVwb has been used for risk stratification within TNM stages [3, 6, 7, [13] [14] [15] [16] , the MTVwb cut-off points in various studies are different for the same TNM stages due to heterogeneity of the tumor burden [6, 7, 16] .
Based on the independent prognostic value of the MTVwb and the variation in patient survival within the same TNM stage, we hypothesized that MTVwb could be used clinically to supplement NSCLC staging through risk stratification, and so developed and validated a novel MTVwb risk stratification system for use in conjunction with the TNM staging system and other prognostic variables. We included a total of 935 consecutive NSCLC patients with FDG-avid tumor, divided into modeling and validation cohorts.
Materials and methods

Patients
This was a retrospective review with Institutional Review Board approval with a waiver of informed consent in patients with NSCLC who underwent baseline FDG PET/CT scans. From the database of our institutional Cancer Center Cancer Registry, we found 2,510 patients with NSCLC who were diagnosed with pathological confirmation and treated at our institution from January 2004 to December 2014. Part of this patient population has been previously analyzed for different purposes and reported [2-5, 15, 16] . The patients were enrolled based on the following inclusion criteria: (1) had undergone a baseline FDG PET/CT scan with a PET-positive tumor, (2) had no evidence of brain metastasis, and (3) did not have a concurrent diagnosis or a history of other primary cancer [17] . A total of 935 patients were identified and divided into a modeling group and a validation group based in the type of PET/CT scanner used to acquire images (Fig. 1) .
The study patients were followed semiannually through our Cancer Registry and through clinical services. The Cancer Registry collected data on demographics, tumor histology, treatment course, patient's last contact date and survival status. The patients' Eastern Cooperative Oncology Group (ECOG) performance score was determined by their treating physicians. The patients' survival status was determined through clinical follow-up and the Social Security Death Index [18] . Overall survival (OS) was the primary endpoint of the study and was defined as the time from the date of the baseline FDG PET/CT scan to the date the patient died of any cause. Patients who were known to be alive at last contact date were censored at the date of last contact. The clinical TNM  stage (stage I, II, III and IV) and clinical TNM substage (IA,  IB, IIA, IIB, IIIA, IIIB, IIIC, IVA and IVB) were determined based on the patient's history, and FDG PET/CT and diagnostic CT findings using the current eighth edition of the TNM staging system [1] .
FDG PET/CT data acquisition and analysis
FDG PET/CT techniques
In our medical center, whole-body FDG PET/CT scans were performed from the thigh to the mid-head in accordance with the National Cancer Institute guidelines [19] . In an early group of 599 patients used to model the MTVwb risk stratification system (64.1%, January 2004 to March 2012), the FDG PET/ CT scans were performed with the scanner described in a prior study (Reveal HD; CTI, Knoxville, TN, USA) [2] . In a later group of 132 patients (14.1%), FDG PET/CT studies were acquired after March 2012 with a Siemens mCT scanner (Siemens Healthcare, Knoxville, TN, USA) [20] . An additional 204 patients (21.8%) with technically adequate PET/CT scans obtained from scanners at external imaging centers were also included. The latter two groups of patients were used for validation of the MTVwb risk stratification system. The patient population was also divided into two randomized cohorts to test the robustness of the novel MTVwb risk stratification system.
Measurements from FDG PET/CT scans
The metabolic tumor volumes (MTV) of FDG-avid tumors throughout the whole body (MTVwb) and the maximum SUVs of the whole-body tumors (SUVmaxwb) were measured by two radiologists using the gradient-based PET Edge tool of the MIM software (MIM Software Inc., Cleveland, OH, USA) as described elsewhere [2, 21] . The tumor contours were determined using attenuationcorrected PET images.
Patients excluded because they had brain metastases before FDG PET/CT (n=51).
Patients excluded because they had no baseline FDG PET/CT (n=1400).
Patients excluded because they had overt double primary malignancy (n=110).
Patients with newly diagnosed/treated NSCLC were retrospectively reviewed (n=2510).
Patients included in the study (n=935).
Patients excluded because they had no FDG-avid tumor (n=14). 
Statistical analyses
The differences between the two cohorts were evaluated with the Pearson chi-squared test for categorical variables and the Wilcoxon rank-sum (Mann-Whitney) test for interval variables.
The MTVwb risk strata and the cut-off values between them were defined based on the quartiles of the MTVwb of the modeling cohort of 599 NSCLC patients. MTVwb risk strata were then tested in both the modeling and the validation cohorts with univariate and multivariate Cox regression models including clinically proven prognostic variables. The prognostic value of the MTVwb risk stratum was also tested for its robustness by randomly assigning the patients into two samples for further validation (see the Supplementary material). Gönen and Heller's concordance indices (GHCIs) were calculated for the models to evaluate their discriminatory power and prognostic accuracy [22] . To compare the GHCIs of the variables in the univariate and multivariate models, a z-test was performed based on 500 bootstrap replications [23] . Kaplan-Meier curves were generated based on MTVwb risk strata with the log-rank test.
The prognostic values of MTVwb tertiles, quartiles and quintiles of the modeling cohort were compared using univariate Cox regression analysis in both the modeling and validation cohorts. All statistical analyses were performed using Stata version 14.0 (StataCorp., College Station, TX, USA).
Data availability
The data supporting the findings can be obtained from the corresponding author's institution.
Results
Characteristics of the modeling and validation cohorts
The characteristics of the patients in both the modeling and the validation cohorts are listed in Table 1 .
In the modeling cohort comprising 599 patients (median age of 68.1 years, 56.1% women), the median OS was 20.5 months with 1-year, 2-year and 5-year OS rates of 64.8%, 46.9% and 27.8%, respectively. The median survival of patients with TNM stages I, II, III and IV were 71.8, 44.8, 15.2, and 9.5 months, respectively. Of the 599 patients, 485 (81.0%) died during follow-up. The median follow-up of the 114 surviving patients was 90 months (25th percentile 71.6 months, 75th percentile 112.4 months). In the validation cohort comprising 336 patients (median age of 67.1 years, 51.2% women), the median OS was 30.5 months with 1-year, 2-year and 5-year OS rates of 73.4%, 55.9% and 32.2%, respectively. The median survival of patients with TNM stages II, III and IV were 51.2, 23.6, and 13.5 months, respectively (patients with TNM stage I, not reached). Of the 336 patients, 211 (62.8%) died during the follow-up. The median follow-up of the 125 surviving patients was 51.3 months (25th percentile 36.9 months, 75th percentile 62.8 months). Figure 2 shows the MTVwb in relation to TNM substage in both the modeling and the validation cohorts, and demonstrates the variation in MTVwb within each TNM substage and the overlap among the substages.
MTVwb, MTVwb risk stratum, SUVmaxwb, race, smoking, tumor histology and ECOG performance score were significantly different between the two cohorts (all p < 0.05). TNM stage, TNM substage, age, gender and treatment were not significantly different between the two cohorts (all p > 0.05; Table 1 ). None of the above patient characteristics was significantly different between the two randomized cohorts (all p > 0.05; Supplementary Table S1 ). Table 2 ). As the TNM substages were included in their respective TNM stage, the rates of concordance and discordance between the TNM substage and the MTVwb risk stratum were therefore 80% and 20%, respectively. Of the 599 patients in the modeling cohort, TNM stage and MTVwb risk stratum were discordant in 270 (45.1%), but the MTVwb risk stratum in a majority of these patients was one above or one below the concordant stratum (36.2%). In the modeling cohort, the rate of discordance in patients with the MTVwb risk stratum deviating by more than one stratum was 8.8%. Of the 336 patients in the validation cohort, TNM stage and MTVwb risk stratum were discordant in 167 (50.3%), but the MTVwb risk stratum in a majority of these patients was one above or one below the concordant stratum (35.4%). In the validation cohort, the rate of discordance in patients with the MTVwb risk stratum deviating by more than one stratum was 14.9%. The rates of discordance in patients with advanced TNM stages (III and IV) were higher than in those with early TNM stages (I and II). For example, in the modeling cohort, the rates of discordance in patients with TNM stage I and those with stage IV were 20% (29/145) and 50.3% (94/187), respectively. Similar trends in discordance rates were present in the validation cohort (18.3% in patients with TNM stage I, and 62.3% in those with TNM stage IV). Furthermore, the rate of discordance between TNM stage and MTVwb risk stratum was equal to the combined rates between the TNM substages of the respective TNM stage and the MTVwb risk stratum. The rates of concordance and discordance between the TNM stage and MTVwb risk stratum are illustrated in Fig. 3 .
MTVwb risk stratum definition
Prognostic value of the MTVwb risk stratification system
Univariate Cox regression analyses
In the modeling cohort, univariate Cox regression analysis (Table 3) MTVwb risk stratum had a significantly greater GHCI than SUVmaxwb (p = 0.021), age (p = 0.002) and ECOG performance score (p = 0.02), as well as other variables including gender, race, smoking history, tumor histology (all p < 0.001).
Multivariate Cox regression analysis
The following five multivariate models were used to compare the independent prognostic values of MTVwb risk strata, TNM stage and TNM substages.
In the modeling cohort, TNM stage, TNM substage, and MTVwb risk stratum, SUVmaxwb, age, gender, race, smoking history, treatment type, and tumor histology were included in three multivariate models to evaluate their joint effect and the adjusted effect of TNM stage, TNM substage and MTVwb risk stratum on OS in models 1-3 (Table 4 ). In models 4 and 5, the effect of MTVwb risk stratum on OS was further evaluated with additional adjustment by TNM stage or TNM substage.
In models 1-3, TNM stage, TNM substage and MTVwb risk stratum (considered separately) remained statistically significant prognostic markers for survival (all p < 0.0001) after adjusting for SUVmaxwb, age, gender, race, smoking history, treatment type and tumor histology. The GHCIs for the models including TNM stage, TNM substage and MTVwb risk stratum were 0.707, 0.715 and 0.708, respectively. The GHCI for the model including TNM stage or TNM substage was not significantly different from that of MTVwb risk stratum (both p > 0.05). In model 4 including TNM stage and MTVwb risk stratum, both remained statistically significant prognostic markers for survival (both p < 0.0001) after adjusting for the same variables as in models 1-3. In model 5 including TNM substage and MTVwb risk stratum, both remained statistically significant prognostic markers for survival (both p < 0.0001) after adjusting for the same variables as in models 1-3. There was no significant difference in the GHCIs between models 4 (0.722) and 5 (0.728; p = 0.068).
In the validation cohort, TNM stage, TNM substage, and MTVwb risk stratum, SUVmaxwb, age, gender, race, smoking history, treatment type, tumor histology and ECOG performance score were included in the multivariate models to evaluate their joint effect on OS (Table 4 ). In models 1-3, TNM stage, TNM substage and MTVwb risk stratum remained statistically significant prognostic markers for survival (all p < 0.0001) after adjusting for SUVmaxwb, age, gender, race, smoking history, treatment type, tumor histology and ECOG performance score. The GHCIs for the models including TNM stage, TNM substage and MTVwb risk stratum were 0.733, 0.735 and 0.742, respectively, and there were no statistically significant differences between them (all p > 0.05). In model 4 including TNM stage and MTVwb risk stratum, MTVwb risk stratum remained a statistically significant prognostic marker for survival after adjusting for the The Kaplan-Meier curves of OS in relation MTVwb risk stratum (Fig. 4a, b) showed that higher MTVwb risk stratum was associated with a worse OS in both the modeling and validation cohorts (both p < 0.0001). The 1-year, 2-year and 5-year survival rates in both the modeling and validation cohorts were similar, as shown in Fig. 4c .
The univariate and multivariate Cox regression analyses and the Kaplan-Meier survival analysis showed that the MTVwb risk stratum had prognostic value independent of TNM stage and other clinical prognostic factors in both randomized cohorts for the sensitivity analyisis (Supplementary  Tables S2 and S3 and Fig. S1 ).
MTVwb tertiles, quartiles (MTVwb risk stratum) and MTVwb quintiles were individually significantly associated with OS (all p < 0.0001) in both the modeling and validation cohorts. There was no significant difference in prognostic power between MTVwb quartiles and MTVwb quintiles (p = 0.13 and p = 0.43, respectively, in the modeling and validation cohorts). However, MTVwb tertiles had lower prognostic power than MTVwb quartiles (p = 0.007 in both cohorts) and MTVwb quintiles (p < 0.001and p = 0.009, respectively, in the modeling and validation cohorts) as measured in terms of C-statistics (Supplementary Table S4 ).
Discussion
The current study used the MTVwb quartiles of the modeling patient cohort to define three cut-off values (10.0, 53.4 and 155 mL) for MTVwb risk strata. Based on the previous finding that the logarithm of MTVwb is prognostic of OS in a linear fashion [2, 4, 5, 15] , we hypothesized that the spread of MTVwb is a crucial measure of prognostic power, and defined MTVwb risk strata (I to IV) as the MTVwb quartiles in the modeling cohort, instead of the direct use of the natural logarithm-transformed MTVwb to further reduce the effect of outliers. Using MTVwb quartiles to define MTVwb risk strata provided an MTVwb risk stratum system comparable to the TNM staging system and avoided small sample sizes in the two systems. Furthermore, MTVwb risk stratum was found to have similar prognostic value to the MTVwb quintiles and better prognostic value than the MTVwb tertiles of the modeling cohort, as measured in terms of C-statistics in both the modeling and validation cohorts (Supplementary Table S4 ). The MTVwb risk strata were then tested in both the modeling and validation cohorts divided based on the PET/CT scanner type using Cox regression and Kaplan-Meier survival The results were robust in the two randomly divided patient cohorts, suggesting that the approach may be generalizable to the general population. Our results also showed that the MTVwb risk stratum and TNM stage are metrics that describe different aspects of underlying tumor activity, as there were large variations in MTVwb within individual TNM substages (Fig. 2) , and 45.1% discordance in the modeling cohort and 50.3% discordance in the validation cohort between MTVwb risk stratum and TNM stage (Table 2 and Fig. 3 ). The prognosis in a patient with a higher MTVwb risk stratum than the current TNM stage may be worse than that in a patient with concordant TNM stage and MTVwb risk stratum, and vice versa ( Fig. 4 and Tables 3 and 4) . Hence, it seems that the treatment type chosen should be adjusted for this prognostic factor. Therefore, our MTVwb risk stratification system provides an additional factor to consider in the treatment decision-making process. There are several important clinical implications of the MTVwb risk stratification system in NSCLC patients. First, because treatment decision-making is affected by the patient's prognosis and MTVwb risk stratum has been demonstrated to be discordant with TNM stage in more than 45% patients and to have prognostic value independent of TNM stage and other clinical prognostic variables, the inclusion of MTVwb risk stratum should allow better treatment decision making in such patients. This is consistent with current oncological practice guidelines that choosing the treatment modality should involve consideration of the visually estimated mediastinal tumor burden in patients with TNM stage III NSCLC [24] . In a patient with TNM stage IV and MTVwb risk stratum II, clinicians may surgically remove primary lung cancer and solitary metastasis. This is consistent with a systematic review of 49 retrospective studies including 2,176 patients with stage IV NSCLC with oligometastases [25] . The review showed that surgical metastasectomy in such patients with limited tumor burden achieved highly variable but improved survival outcomes, with 5-year OS rates of 10-80%.
Second, the improved estimate of survival provided by using MTVwb risk stratum along with established prognostic variables may help in future treatment planning by weighing the cost and benefit of individualized treatment, and hence increase the patient centeredness of the treatment and patient satisfaction. Finally, the MTVwb risk stratum could be used in clinical trials to better define experimental and control patient populations by addressing the potential heterogeneity among patients. Refining the estimate of OS using MTVwb risk stratum, after estimating OS using the clinically established variables including TNM stage, may lead to more effective and more efficient trials.
In the current study the FDG PET/CT scans of the modeling and validation cohorts were performed with different scanners at the same institution or different institutions, as described in the section BFDG PET/CT techniques and the modeling and validation cohorts had significantly different MTVwb values, MTVwb risk strata, SUVmaxwb, race, smoking history, tumor histology and ECOG performance score. Therefore, the FDG PET/CT scanners used in the study and the clinical variables in the modeling and validation cohorts mimic real world situations, suggesting that the MTVwb risk stratification system developed and validated in this study survival and MTVwb in patients with NSCLC in different parts of the world, and with different PET/CT scanners [2-11, 13, 14, 26-30] , (4) the variability in MTV of primary NSCLC tumors is less than that of SUV of primary NSCLC tumors from PET scans with FDG uptake times of 1 h and 2 h [31] ; and (5) MTVwb measurements show relatively low interobserver variability [2, 5] .
This study had several limitations. First, this was a retrospective study and therefore the treatment of the patients was determined by the prevailing clinical protocols at the time of each patient's management. Second, the ECOG performance score was only included in the analysis of the validation cohort in the multivariate Cox models because the performance score was not available in 18.9% (113) of the 599 patients in the modeling cohort. Third, the cut-off values for the MTVwb risk strata were based on a sample from a single site. Although the distribution of TNM stages in this sample appeared similar to that of a national sample [32, 33] , multicenter studies are needed to validate the cut-off values for the MTVwb risk strata for the typical NSCLC patient population.
Conclusion
In this study we developed and validated a novel MTVwb risk stratification system, which has a prognostic value independent of TNM stage and other clinical prognostic factors in patients with NSCLC, suggesting that it could be used for further NSCLC pretreatment assessment and for refining treatment decisions in individual patients.
